Optiscan has been featured in a Stockhead article, which has also appeared in The Australian and 11 News Corp mastheads, highlighting the US commercial launch of its InSpecta veterinary imaging platform and the company’s transition to a commercial-stage medical technology business.

The article notes that the launch follows Optiscan’s regulatory dossier submission to the US Food and Drug Administration’s Center for Veterinary Medicine (FDA CVM), enabling US commercial sales of InSpecta. It highlights that the launch establishes a validated regulatory and commercial pathway for the company’s broader product portfolio, while expanding MedTechCo’s proprietary imaging technology into the growing US veterinary market.

The report also covers the official launch ofInSpecta at the American Veterinary Medical Association (AVMA) Convention 2026, where the company is showcasing the device to veterinary clinicians, specialists and practice decision-makers from across the United States.

"It comes hot on the heels of our FDA CVM submission for InSpecta and means we can now get cracking with the commercialisation of this device, which is targeting a slice of the world’s largest veterinary healthcare market. Optiscan InSpecta has been designed specifically for veterinary practices servicing this large and growing US market. It will deliver veterinarians immediate cellular insight at the point of care allowing them to offer advanced imaging capability in-house,” Optiscan CEO and Managing Director Dr. Camile Farah.

Stockhead – Read the full article here.
The Australian – Read the full article here.